BPC-157 / TB-500
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
The “Wolverine stack” is a pre-mixed blend of two peptides — BPC-157 and TB-500 — sold as a single combined vial, often from compounding pharmacies. It’s one of the most popular pairings discussed in recovery circles, marketed toward injury recovery and tissue repair.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice, studied primarily for connective-tissue and gut healing. TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in cell migration and wound repair. The blend combines the two so that a single injection covers both.
Evidence for each component comes almost entirely from animal models, and there is little to no clinical research on the combination itself. Neither peptide is approved by any major regulator for human therapeutic use.
How it works
The two peptides are commonly described as complementary. In preclinical studies, BPC-157 appears to promote angiogenesis — the formation of new blood vessels — and to influence growth-factor pathways tied to tendon and ligament healing. TB-500, as a thymosin beta-4 analog, is studied for its role in regulating actin, a protein central to cell movement, which may support the migration of repair cells to injured tissue.
The rationale for stacking is that these mechanisms overlap without fully duplicating each other. It’s important to note that this complementary picture is inferred from separate studies of each peptide; the combined mechanism in humans has not been established.
Reported benefits
- Faster recovery from tendon, ligament, and muscle injuries (animal data)
- Support for new blood-vessel formation and blood flow to injured areas
- Enhanced migration of repair cells and re-epithelialization in wound models
- Reduced inflammation at sites of injury
These are reported and studied effects for the individual components, not guaranteed outcomes for the blend.
Considerations & side effects
Because human trials are lacking for both peptides — and absent for the combination — the long-term safety profile of the Wolverine stack is not well characterized. Reported side effects for the components are generally described as mild and include injection-site irritation, occasional lightheadedness, fatigue, and nausea.
Purity and the actual ratio of the two peptides can vary widely in the research-chemical and compounding market, and a single pre-mixed vial makes it harder to adjust either component independently. This blend is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is the Wolverine stack?
A pre-mixed blend combining two peptides — BPC-157 and TB-500 (thymosin beta-4) — sold in a single vial. It's one of the most popular healing combinations, used in recovery-focused protocols for injury and tissue repair.
Why are BPC-157 and TB-500 combined?
The two are often paired because they're studied for complementary, overlapping recovery pathways — BPC-157 for connective-tissue and gut repair, and TB-500 for cell migration and new blood-vessel formation. Combining them into one vial is meant to simplify a dual-peptide protocol.
Is the Wolverine stack FDA-approved?
No. Neither BPC-157 nor TB-500 is approved by the FDA or any major regulator for human therapeutic use, and the blend is sold for research purposes only.
How is the blend typically administered?
Most commonly by subcutaneous injection after reconstitution with bacteriostatic water, since both components are supplied as a lyophilized powder.
Is human evidence available for the combination?
Direct clinical data on the specific blend is essentially absent. Most of what's known comes from separate animal studies of each individual peptide, so any combined effect in humans is not established.
References
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. ↗
- Xing Y, et al. Progress on the Function and Application of Thymosin β4. Front Endocrinol. 2021. ↗
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
Related compounds
Body Protection Compound-157. A pentadecapeptide derived from human gastric juice. Known for tissue healing, gut health, and injury recovery.
Four-peptide regenerative blend combining GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg). Advanced healing and anti-inflammatory protocol. Sold as a single 80mg pre-mixed vial.
An arginate-salt formulation of the BPC-157 pentadecapeptide (also sold as 'PDA'). The arginine salt buffers the peptide across a wider pH range, improving stability and oral bioavailability versus the standard acetate form. Same healing uses as BPC-157.